Research and Markets: Global Hormone Refractory Breast Cancer Pipeline Insights 2016

DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/lnhlkf/hormone)
has announced the addition of the “Hormone
Refractory Breast Cancer-Pipeline Insights, 2016”
report to
their offering.

Hormone Refractory Breast Cancer-Pipeline Insights, 2016 provides in
depth insights on the pipeline drugs and their development activities
around the Hormone Refractory Breast Cancer. The report covers the
product profiles in various stages of development including Discovery,
Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other
development activities including technology, licensing, collaborations,
acquisitions, fundings, patent and USFDA & EMA designations details.

The report also provides detailed information on the discontinued and
dormant drugs that have gone inactive over the years for Hormone
Refractory Breast Cancer.

The report also assesses the Hormone Refractory Breast Cancer
therapeutics by Monotherapy, Combination products, molecule type and
Route of Administration.

Scope

  • The report provides competitive pipeline landscape of Hormone
    Refractory Breast Cancer
  • The report provides pipeline products under drug profile section which
    includes product description, MOA, licensors & collaborators,
    development partner and chemical information
  • Coverage of the Hormone Refractory Breast Cancer pipeline on the basis
    of target, MOA, route of administration, technology involved and
    molecule type
  • The report reviews key players involved in the therapeutics
    development for Hormone Refractory Breast Cancer and also provide
    company profiling
  • The report also gives the information of dormant and discontinued
    pipeline projects
  • Pipeline products coverage based on various stages of development
    ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy
    products, stage of development and molecule type

Key Topics Covered:

  1. Hormone Refractory Breast Cancer Overview
  2. Hormone Refractory Breast Cancer Pipeline Therapeutics
  3. Hormone Refractory Breast Cancer Therapeutics under Development by
    Companies
  4. Hormone Refractory Breast Cancer Filed and Phase III Products
  5. Comparative Analysis
  6. Hormone Refractory Breast Cancer Phase II Products
  7. Comparative Analysis
  8. Hormone Refractory Breast Cancer Phase I and IND Filed Products
  9. Comparative Analysis
  10. Hormone Refractory Breast Cancer Discovery and Pre-Clinical Stage
    Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. Hormone Refractory Breast Cancer – Therapeutics Assessment
  14. Assessment by Monotherapy Products
  15. Assessment by Combination Products
  16. Assessment by Route of Administration
  17. Assessment by Molecule Type
  18. Hormone Refractory Breast Cancer – Discontinued Products
  19. Hormone Refractory Breast Cancer – Dormant Products
  20. Companies Involved in Therapeutics Development for Hormone Refractory
    Breast Cancer

For more information visit http://www.researchandmarkets.com/research/lnhlkf/hormone

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare
and Medical Devices
, Pharmaceuticals